#United States #New York #Pomerantz LLP #Foghorn Therapeutics #FHTX

Pomerantz Law Firm Investigates Foghorn Therapeutics' Business Practices

In an important development for investors, the Pomerantz Law Firm has initiated an investigation into Foghorn Therapeutics Inc. (NASDAQ: FHTX) over allegations of potential securities fraud and other unlawful business practices. This investigation comes in light of significant changes within the company that have triggered concern among its shareholders.

Background of Foghorn Therapeutics

Foghorn Therapeutics, a biopharmaceutical company known for its innovative approaches to treating genetic disorders, recently made headlines on October 1, 2026. In a press release, the company disclosed its decision to cease further development on two clinical programs - the FHD-909 (LY4050784) and the Selective SMARCA2 degrader program. This decision marks a significant shift in Foghorn's strategy, as the collaborations with Lilly for these programs will not advance to the next phase.

Foghorn’s Chief Executive Officer, Adrian Gottshalk, indicated that the company would be redirecting its focus towards its proprietary portfolio, asserting that these programs hold the greatest potential to meet urgent patient needs and ultimately enhance long-term value for the company and its investors. As a part of this strategy re-alignment, Foghorn also announced a significant reduction in workforce, implicating a 40% workforce reduction aimed at conserving cash to support its prioritized programs until the latter part of 2029.

Shareholder Impact and Stock Price Reaction

The announcement of the halted programs and workforce reduction had an immediate effect on Foghorn’s stock performance. Following the news, the company’s stock price plummeted by $0.90, a staggering 30.82% drop, closing at $2.02 per share on October 2, 2026. This sharp decline underscores the negative impact of the company’s operational changes on investor confidence and market perception.

Implications of the Investigation

Given these developments, Pomerantz LLP aims to uncover whether Foghorn’s management engaged in conduct that could be classified as securities fraud or other unlawful practices impacting investors. The firm is well-regarded in the field of securities class actions, having a long history of advocating for shareholders who have been victimized by corporate misconduct.

Investors with grievances or concerns are encouraged to reach out to Danielle Peyton at Pomerantz LLP, either by email or by calling directly for further assistance and information regarding potential participation in a class action lawsuit. The firm's commitment to investigating this matter reflects their ongoing dedication to upholding investor rights and accountability among corporate executives.

Conclusion

As the situation unfolds, Foghorn Therapeutics must navigate the fallout from its recent announcements while addressing investor concerns. The Pomerantz investigation could shed light on the ethical obligations of the company’s leadership and the implications of their decisions on stakeholder interests. Investors are advised to stay tuned for further updates regarding this inquiry and its potential ramifications on Foghorn’s future operations.

For additional details or to express concerns, investors should not hesitate to contact the Pomerantz Law Firm for guidance and possible involvement.